skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Lutetium Lu 177 DOTA-Tetulomab (Code C105403)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Lutetium Lu 177 DOTA-Tetulomab

Definition: A radioimmunoconjugate, which consists of a monoclonal antibody against the cell-surface antigen CD37 covalently linked, via the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. The antibody moiety of lutetium Lu 177 DOTA-tetulomab binds to CD37 on tumor B-cells. Upon internalization, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.

Display Name: Lutetium Lu 177 DOTA-Tetulomab

Label: Lutetium Lu 177 DOTA-Tetulomab

NCI Thesaurus Code: C105403 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL446324  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Lutetium Lu 177 DOTA-Tetulomab

External Source Codes: 
PDQ Closed Trial Search ID 746917
PDQ Open Trial Search ID 746917 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C105403
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom